### Causally Associations of Blood Lipids Levels with COVID-19 Risk: Mendelian Randomization

- 2 Study
- 3 Kun Zhang, <sup>1,3</sup> Yan Guo, <sup>1,3</sup> Zhuo-Xin Wang, <sup>1</sup> Jing-Miao Ding, <sup>1</sup> Shi Yao, <sup>1</sup> Hao Chen, <sup>1</sup> Dong-Li Zhu, <sup>1</sup> Kun
- 4 Zhang,<sup>2</sup> Wei Huang,<sup>2</sup> Shan-Shan Dong, <sup>1,\*</sup> Tie-Lin Yang<sup>1,2,\*</sup>
- 6 <sup>1</sup>Key Laboratory of Biomedical Information Engineering of Ministry of Education, Biomedical
- 7 Informatics & Genomics Center, School of Life Science and Technology, Xi'an Jiaotong University,
- 8 Xi'an, Shaanxi, P. R. China, 710049

1

- <sup>9</sup> Department of Trauma Surgery, Honghui Hospital, College of Medicine, Xi'an Jiaotong University,
- 10 Xi'an, Shaanxi, P. R. China, 710054
- 11 These authors contributed equally to this study.
- \*Correspondence: yangtielin@xjtu.edu.cn; dongss@xjtu.edu.cn

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

2

Abstract **Background:** Coronavirus disease 2019 (COVID-19) is a global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). It has been found that coronary artery disease (CAD) is a comorbid condition for COVID-19. As the risk factors of CAD, whether blood lipids levels are causally related to increasing susceptibility and severity of COVID-19 is still unknown. Design: We performed two-sample Mendelian Randomization (MR) analyses to explore whether dyslipidemia, low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDLc), triglyceride (TG) and total cholesterol (TC) were causally related to COVID-19 risk and severity. The GWAS summary data of blood lipids involving in 188,578 individuals and dyslipidemia in a total of 53,991 individuals were used as exposures, respectively. Two COVID-19 GWASs including 1,221 infected patients and 1,610 severe patients defined as respiratory failure were employed as outcomes. Based on the MR estimates, we further carried out gene-based and gene-set analysis to explain the potential mechanism for causal effect. Results: The MR results showed that dyslipidemia was casually associated with the susceptibility of COVID-19 and induced 27% higher odds for COVID-19 infection (MR-IVW OR = 1.27, 95% CI: 1.08 to 1.49, *p-value* =  $3.18 \times 10^{-3}$ ). Moreover, the increasing level of blood TC will raise 14 % higher odds for the susceptibility of COVID-19 (MR-IVW OR = 1.14, 95% CI: 1.04 to 1.25, p-value =  $5.07 \times 10^{-3}$ ). Gene-based analysis identified that ABO gene was associated with TC and the gene-set analysis found

**Conclusions:** We obtained three conclusions: 1) Dyslipidemia is casually associated with the susceptibility of COVID-19; 2) TC is a risk factor for the susceptibility of COVID-19; 3) The different susceptibility of COVID-19 in specific blood group may be partly explained by the TC concentration

that immune processes were involved in the risk effect of TC.

in diverse ABO blood groups.

36

37 Key words: Blood lipids; COVID-19; Mendelian randomization; ABO; Immunity

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

4

Introduction Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome, coronavirus 2 (SARS-Cov-2) is a global pandemic <sup>1, 2</sup>. This disease progresses from asymptomatic to acute respiratory distress syndrome and multiple organ dysfunction, and has become a major threat to public health in more than 160 countries <sup>1,2</sup>. As of June 26, 2020, there were more than 9.69 million confirmed cases, with total deaths increasing to 487,997 worldwide. Considering the severity of COVID-19, it is urgent to explore the susceptibility factors of COVID-19, which is helpful to develop effective policies and personalized treatments to control the spread of the disease to susceptible groups. Recent studies <sup>1, 2</sup> have found that more than 20% of the confirmed cases had a history of coronary artery disease (CAD). Blood lipids, including low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c), triglyceride (TG) and total cholesterol (TC) are heritable and modifiable risk factors for CAD 3, 4. However, whether blood lipids levels are causally related to increasing susceptibility and severity for COVID-19 is still unknown. Mendelian randomization (MR) is an epidemiological method in which environmental exposure-related genetic variations are used as instrumental variables (IVs) to evaluate the association between exposures and outcomes <sup>5, 6</sup>. It can avoid the issues of confusion and has been demonstrated as an effective strategy to identify causal effect <sup>5-10</sup>. In this study, we conducted a two-sample Mendelian randomization study to explore the possible causal associations between blood lipids and COVID-19 susceptibility and severity, and investigate the potential mechanisms underlying the causal effect.

Methods 60 A step-by-step workflow in this study is presented in Figure 1. 61 62 Datasets used in this study 63 Blood lipids 64 We collected data for HDL-c, LDL-c, TG and TC from a published genome-wide association study 65 (GWAS) <sup>3</sup> (http://csg.sph.umich.edu//abecasis/public/lipids2013/) involving in a total of 188,578 66 67 European-ancestry individuals. GWAS summary data of dyslipidemia was obtained from the Genetic 68 Epidemiology Research on Adult Health and Aging (GERA) (https://cnsgenomics.com/content/data) with 53,991 individuals <sup>10</sup>. 69 COVID-19 70 71 For assessment of associations with COVID-19 risk, we used the latest COVID-19 GWAS results from GRASP database (https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx). The phenotype used in this 72 GWAS was case/control for COVID-19 infection containing 1,221 positive COVID-19 tests and 4,117 73 74 negative tests from UK Biobank individuals (released on June 5, 2020). To explore the causal effect of blood lipids on severity of COVID-19, we also accessed GWAS of severe COVID-19 defined as 75 respiratory failure <sup>11</sup> (http://www.c19-genetics.eu/). This GWAS included 1,610 severe COVID-19 76 patients and 2,205 control participants from Italy and Spain. These two GWASs were all conducted with 77 78 the correction of age, sex and top 10 principal components. 79 80 **Data Harmonization Process** 

For each exposure GWAS, we performed harmonization process using the following criteria:

- 82 1) Remove the SNPs located in major histocompatibility complex (MHC) region.
- 83 2) Select the SNPs with a common frequency of the effect allele (EAF) (> 0.01 and < 0.99).
- 84 3) Standardize the effect size (β) and standard error (se) for each GWAS data with the function of minor
- allele frequency and sample size using the following formula <sup>12</sup>:

86 
$$\beta = \frac{z}{\sqrt{2p(1-p)(n+z^2)}}, se = \frac{1}{\sqrt{2p(1-p)(n+z^2)}}$$

- where  $z = \beta$ /se from the original summary data, p is the minor allele frequency, and n is the total sample
- 88 size.

89

90

99

100

#### Instrumental variables (IVs) selection

- 91 We selected independent and genome-wide significant GWAS SNPs of HDL-c, LDL-c, TG, TC and
- dyslipidemia by use of the clumping algorithm in PLINK (http://pngu.mgh.harvard.edu/purcell/plink/)
- 93 13 at a suggestive threshold ( $r^2$  threshold = 0.001, window size = 1 Mb, *p-value* = 5 × 10<sup>-8</sup>). The 1000
- 94 Genomes Project (http://www.internationalgenome.org/) data were used as the reference for linkage
- 95 disequilibrium (LD) estimation. For each outcome, we then removed outlier pleiotropic SNPs using
- 96 RadialMR <sup>14</sup> with the *p-value* threshold of 0.05. RadialMR <sup>14</sup> identified outlying genetic instruments
- via heterogeneity test (modified Q-statistics). After the removal of pleiotropy, the remaining exposure
- 98 related SNPs for each outcome as instrumental variables (IVs) were utilized to perform MR analyses.

## MR analyses and pleiotropy assessment

- We conducted four complementary two-sample MR methods, including Inverse-Variance Weighted
- 102 (IVW) method, weighted median method, weighted mode method and MR-Egger method, which make
- different assumptions about horizontal pleiotropy.

The IVW method assumes balanced pleiotropy <sup>15</sup>. The pleiotropy is assessed via Cochran's Q statistic and presented as excessive heterogeneity which will inflate the estimate of MR analysis <sup>16</sup>. The MR-Egger method is based on the assumption which indicate instrument strength independent of the direct effects <sup>15</sup>. MR-Egger estimates can be also evaluated by the regression dilution I<sup>2</sup> (GX) <sup>17</sup> according to the assumption that no measurement error in the SNP exposure effects. If I<sup>2</sup>(GX) <sup>17</sup> was sufficiently low (I<sup>2</sup>  $_{(GX)}$  < 0.9), the correction analysis was conducted to assess the causal effect by SIMEX. The intercept term of MR-Egger method can used for evaluating the directional pleiotropic effect <sup>18</sup>. When the intercept is zero or its *p-value* was not significant (*p-value* > 0.05) were considered as non-pleiotropy. Moreover, we also used the Rucker's Q' statistic <sup>19</sup> to measure the heterogeneity for MR-Egger method. If the difference Q - Q' is sufficiently extreme with respect to a  $\chi 2$  distribution with the 1 degree of freedom, we indicated that directional pleiotropy is an important factor and MR-Egger model provides a better fit than the IVW method <sup>20</sup>. All methods of two-sample MR analyses were measured by TwoSampleMR package in R. For various estimates for different measures, we select the main MR method as following rules: 1) If no directional pleiotropy in MR estimates (Q statistic: p-value > 0.05, MR-Egger intercept: intercept = 0 or p-value > 0.05, Q – Q': p-value > 0.05), IVW method was used. 2) If directional pleiotropy was detected (MR-Egger intercept: intercept  $\neq 0$  and p-value < 0.05, Q – Q': p-value < 0.05) and p-value > 0.05 for the test of Q', MR-Egger method was used. 3) If directional pleiotropy was detected (MR-Egger intercept: intercept  $\neq 0$  and p-value < 0.05, Q – Q': p-value < 0.05) and p-value < 0.05 for the test of Q', weighted median method was used.

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

8

Sensitivity analysis Leave-one-out sensitivity analysis was implemented to assess whether any significant results were generated by a specific SNP in IVW models. Gene-based and gene-set analysis MAGMA (https://ctg.cncr.nl/software/magma) <sup>21</sup> is commonly used for gene and gene-set analyses based on GWAS and genotype data. In order to explore the association of TC and COVID-19, we implemented MAGMA to identify genes and gene sets in which multiple SNPs show moderate association to TC without reaching the stringent genome-wide significance level. Genome-wide gene-based association study The genome-wide gene-based association study (GWGAS) is based on the model of multiple linear principal components regression and calculated the gene p-value using F-test <sup>22</sup>. All 19,427 proteincoding genes from the NCBI 37.3 gene definitions were employed for SNPs annotation. We mapped SNPs to genes by a defined window around each gene of 2kb away from the transcription start site (TSS) upstream and 1kb away from the transcription stop site downstream based on human reference assembly (GRCh37 or hg19) <sup>23</sup>. The GWGAS analysis was performed to quantify the degree of association for each gene to TC and to compute the correlations between genes are estimated according to LD statistics. The LD reference was also from Phase 3 of 1,000 Genomes. Gene-set analysis The gene-set analysis is built as an independent layer around the gene analysis, while it also on the strength of the gene p-value and gene correlation matrix from the previous step in order to compensate for the dependencies between genes <sup>22</sup>. A total of 7,521 gene sets were derived from Gene Ontology

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

9

(GO) biological processes and the 186 pathways from Kyoto Encyclopedia of Genes and Genomes (KEGG) as auxiliary files for gene-set analysis, which obtained from the Molecular Signatures Database (MSigDB) version 6.0 (https://www.gsea-msigdb.org/gsea/downloads.jsp). **Multiple testing correction** We employed false discovery rate (FDR) to address multiple comparisons issue and the adjusted pvalue < 0.05 was used for judging significance. For MR estimates, we adopted an FDR control procedure for the susceptibility and severity of COVID-19 separately. Results IVs selection After data harmonization and clumping, we identified 20 SNPs, 101 SNPs, 79 SNPs, 59 SNPs and 98 SNPs for dyslipidemia, HDL-c, LDL-c, TG and TC, respectively. For each outcome, the final IVs are shown in Table S1. Causal effect of dyslipidemia on COVID-19 We evaluated whether dyslipidemia is causally related to COVID-19 firstly. The assessment of pleiotropy is shown in Table S1. Since there was no significant evidence of pleiotropy (all p value > 0.05, Table S1), we chose IVW as the main MR method. We found that dyslipidemia was causally associated with the susceptibility of COVID-19 after FDR correction (MR-IVW p-value =  $3.18 \times 10^{-3}$ , FDR =  $1.30 \times 10^{-2}$ ) (Table 1). The estimate of IVW showed that dyslipidemia could raise 27% odds for the infection risk of COVID-19 (MR-IVW OR = 1.27, 95% CI: 1.08 to 1.49) (Figure 2). Besides the

IVW method, the weighted median and MR-Egger tests also showed consistent causal associations (MR-Weighted median OR = 1.26, 95% CI: 1.01 to 1.56, p-value =  $4.00 \times 10^{-2}$ ; MR-Egger OR = 1.53, 95% CI: 1.12 to 2.10, p-value =  $2.00 \times 10^{-2}$ ) (Table 1). However, dyslipidemia had no causally relevance to severe COVID-19 (Table 1 and Figure 2). In sensitivity analyses, the results of leave-one-out permutation didn't find individual influential SNPs in IVW models (p-value < 0.05) (Figure S1).

# Causal effect of blood lipids on COVID-19

We further assessed the causal effects of blood lipids levels, including HDL-c, LDL-c, TC and TG on COVID-19 to identify the specific risk lipid. We didn't detect any evidence of pleiotropy as well (all p value > 0.05, Table S1), thus we still chose IVW as the main MR method. We identified TC was a risk factor for the susceptibility of COVID-19 (MR-IVW p-value =  $5.07 \times 10^{-3}$ , FDR =  $1.30 \times 10^{-2}$ ) (Table 1). As shown in Figure 2, the increasing concentration of TC in blood could induce 14 % higher odds of COVID-19 infection risk (MR-IVW OR = 1.14, 95% CI: 1.04 to 1.25). Besides, the weighted median test also showed a causal association (MR-Weighted median OR = 1.23, 95% CI: 1.06 to 1.43, p-value =  $5.00 \times 10^{-3}$ ) (Table 1). Leave-one-out analysis indicated that no single SNP was driving the causal estimates (Figure S1). We also measured the relationship between four blood lipids and severe COVID-19. Consistent with dyslipidemia, there was no causal effects for blood lipids-COVID-19 severity pairs.

# Gene-based and gene-set analyses for TC

In our above results, we have discovered the risk effect of TC to the susceptibility of COVID-19. We wonder explain the internal linkage between TC and COVID-19 preliminarily, thus we investigated the potential mechanism of TC by gene-based and gene-set analysis.

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

11

Gene-based analysis for TC For gene-based analysis, a total of 17,699 genes which were represented by at least one SNP were identified. After correction for multiple testing, we identified 668 genes linked to TC (Figure 3A and Table S2). It should be noticed that ABO was identified to be associated with TC significantly (p-value  $= 6.80 \times 10^{-11}$ , FDR  $= 1.43 \times 10^{-8}$ ). Some observational studies have found that the level of blood lipids was related to ABO blood group and Table 2 lists the detailed information about these observational studies <sup>24-29</sup>. All of these studies provide a conclusion that TC is higher in A or non-O blood group, but lower in O blood group. On the other side, GWAS on severe COVID-19 has revealed the relationship between ABO blood group locus and COVID-19 11. It has been found a higher risk in blood group A than in other blood group and a protective effect in blood group O, which was coincident with the results of observational investigations based on phenotype <sup>30-32</sup>. In general, we inferred that the different susceptibility of COVID-19 in specific blood group may be partly explained by the TC levels in diverse ABO blood group (Figure 3B). Gene-set analysis for TC For the GO biological processes, we identified 89 processes significantly associated with TC (FDR < 0.05), which are mostly involved in lipid metabolism (Table S3). For the KEGG pathways, we just identified 2 pathways (Carbohydrate metabolism and Glycan biosynthesis and metabolism) significantly associated with TC after FDR corrections. Besides, we also found 20 KEGG pathways with nominally significant associations with TC (p-value < 0.05) (Table S4). In all related processes/pathways, six of them are related to immune response and may participate in the infection and progression of COVID-19, including negative regulation of lymphocyte mediated immunity,

interleukin-10 biosynthetic process, interferon-β (INF-β) biosynthetic process, Fc gamma R-mediated

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

12

phagocytosis, antigen processing and presentation and primary immunodeficiency. The dysfunction of immunity would induce poor immune response for SARS-CoV-2 infection, which cause lung and systemic pathology <sup>33, 34</sup>. **Discussion** In this study, we implemented two-sample MR analyses to explore the possible causal associations between blood lipids and COVID-19. We have found potential causal effects of dyslipidemia and blood TC on the infected risk of COVID-19. To explain the potential influence of TC on COVID-19, we explored the TC-related genes and gene sets. It is notable that ABO gene performs quite strong relevance to TC, which was also reported by previous GWAS of TC<sup>3</sup>. Besides, some observational studies have found that the blood lipids level was related to ABO blood group. The higher level of TC was found in non-O blood group and was significantly associated with an increased prevalence of CVD <sup>24-29</sup>. In addition, The GWAS of severe COVID-19 has identified the association signal at ABO blood group locus 11. Based on the blood-group-specific analysis, they observed a higher risk of COVID-19 in blood group A than in other blood group and a protective effect in blood group O, which was coincident with the results of observational investigations based on phenotype 30-32. In summary of these results, we inferred that the different susceptibility of COVID-19 in specific blood group may be partly explained by the TC concentration in diverse ABO blood groups.

The result of gene-set analysis identified a total of 89 biological processes and 20 pathways associated

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

13

In summary, we carried out a two-sample MR design for blood lipids and COVID-19, and obtained

following conclusions: 1) Dyslipidemia is causally associated with the susceptibility of COVID-19; 2) The higher total cholesterol level will increase the susceptibility of COVID-19; 3) The different susceptibility of COVID-19 in specific blood group may be partly explained by the TC concentration in diverse ABO blood groups; 4) The risk effect of total cholesterol on COVID-19 may be mediated by the dysfunction of immunity.

Conflict of Interest

The authors have nothing to disclose.

Acknowledgements

This study is supported by National Natural Science Foundation of China (31871264, 31970569);

Zhejiang Provincial Natural Science Foundation of China (LGF18C060002); Shannxi Provincial key research and development plan (2019ZDLSF01-09) and the Fundamental Research Funds for the Central Universities (xzy032020039, xzy032020023).

#### Reference

- 1. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DSC, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England journal of medicine*. 2020;382:1708-1720.
- 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*. 2020;395:497-506.
- 3. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, et al. Discovery and refinement of loci associated with lipid levels. *Nature Genetics*. 2013;45:1274-1283.
- 4. WP C. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. *The Canadian journal of cardiology*. 1988:5A-10A.
- 5. Boef AGC, Dekkers OM and le Cessie S. Mendelian randomization studies: a review of the approaches used and the quality of reporting. *International Journal of Epidemiology*. 2015;44:496-511.
- 6. Sleiman PMA and Grant SFA. Mendelian Randomization in the Era of Genomewide Association Studies. *Clinical Chemistry*. 2010;56:723.
- 7. Davies NM, von Hinke Kessler Scholder S, Farbmacher H, Burgess S, Windmeijer F and Smith GD. The many weak instruments problem and Mendelian randomization. *Stat Med.* 2015;34:454-468.
- 8. Burgess S, Thompson SG and Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. *International Journal of Epidemiology*. 2011;40:755-764.
- 9. Davey Smith G and Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?\*. *International Journal of Epidemiology*. 2003;32:1-22.
- 10. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, Robinson MR, McGrath JJ, Visscher PM, Wray NR, et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nature communications*. 2018;9:224-224.
- 11. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernández J, Prati D, Baselli G, Asselta R, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *The New England journal of medicine*. 2020:NEJMoa2020283.
- 12. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, Montgomery GW, Goddard ME, Wray NR, Visscher PM, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nature Genetics*. 2016;48:481-487.
- 13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *American journal of human genetics*. 2007;81:559-575.
- 14. Bowden J, Spiller W, Del Greco M F, Sheehan N, Thompson J, Minelli C and Davey Smith G. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. *International journal of epidemiology*. 2018;47:1264-1278.
- 15. Bowden J, Davey Smith G and Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *International journal of epidemiology*. 2015;44:512-525.
- 16. G CW. The combination of estimates from different experiments. *Biometrics*. 1954;10:28.

- 18. Hemani G, Bowden J and Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Human molecular genetics*. 2018;27:R195-R208.
- 19. Rücker G, Schwarzer G, Carpenter JR, Binder H and Schumacher M. Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis. *Biostatistics*. 2010;12:122-142.
- 20. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N and Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat Med.* 2017;36:1783-1802.
- 21. de Leeuw CA, Mooij JM, Heskes T and Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS computational biology*. 2015;11:e1004219-e1004219.
- 22. de Leeuw CA, Neale BM, Heskes T and Posthuma D. The statistical properties of gene-set analysis. *Nature Reviews Genetics*. 2016;17:353-364.
- 23. Nagel M, Jansen PR, Stringer S, Watanabe K, de Leeuw CA, Bryois J, Savage JE, Hammerschlag AR, Skene NG, Muñoz-Manchado AB, et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. *Nature Genetics*. 2018;50:920-927.
- 24. Franchini M, Mengoli C, Capuzzo E, Terenziani I, Bonfanti C and Lippi G. Correlation between ABO Blood Group, and Conventional Hematological and Metabolic Parameters in Blood Donors. *Semin Thromb Hemost.* 2016;42:075-086.
- 25. Chen Y, Chen C, Ke X, Xiong L, Shi Y, Li J, Tan X and Ye S. Analysis of Circulating Cholesterol Levels as a Mediator of an Association Between ABO Blood Group and Coronary Heart Disease. *Circulation: Cardiovascular Genetics*. 2014;7:43-48.
- 26. Gillum RF. Blood groups, serum cholesterol, serum uric acid, blood pressure, and obesity in adolescents. *Journal of the National Medical Association*. 1991;83:682-688.
- 27. Cetin MS, Ozcan Cetin EH, Aras D, Topaloglu S, Temizhan A, Kisacik HL and Aydogdu S. Non-O blood groups can be a prognostic marker of in-hospital and long-term major adverse cardiovascular events in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Thrombosis Research*. 2015;136:599-605.
- 28. Paquette M, Dufour R and Baass A. ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia. *Journal of Clinical Lipidology*. 2018;12:383-389.e1.
- 29. Li S, Xu R-X, Guo Y-L, Zhang Y, Zhu C-G, Sun J and Li J-J. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9. *Nutrition, Metabolism and Cardiovascular Diseases*. 2015;25:411-417.
- 30. Wu Y, Feng Z, Li P and Yu Q. Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. *Clinica Chimica Acta*. 2020;509:220-223.
- 31. Zietz M and Tatonetti NP. Testing the association between blood type and COVID-19 infection, intubation, and death. *medRxiv*: the preprint server for health sciences. 2020:2020.04.08.20058073.
- 32. Cheng Y, Cheng G, Chui CH, Lau FY, Chan PKS, Ng MHL, Sung JJY and Wong RSM. ABO Blood Group and Susceptibility to Severe Acute Respiratory Syndrome. *JAMA*. 2005;293:1447-1451.
- 33. Tay MZ, Poh CM, Rénia L, MacAry PA and Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. *Nature reviews Immunology*. 2020;20:363-374.
- 34. Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, Quan S, Zhang F, Sun R, Qian L, et al. Proteomic and

Metabolomic Characterization of COVID-19 Patient Sera. Cell. 2020:S0092-8674(20)30627-9.

**Figure Legends** 

Figure 1. The MR analysis pipeline of the current study.

Figure 2. Causal effects of dyslipidemia and TC on COVID-19. Summary of the Mendelian

randomization (MR) estimates derived from the main inverse-variance weighted, MR-Egger, weighted

median and weighted mode-based methods for dyslipidemia and TC to the susceptibility of COVID-19

(COVID-19).

Figure 3. The relationships among the TC level, the susceptibility of COVID-19 and the different

**ABO blood group.** A. Results of gene-based analysis. The dots above the red line represents the genes

significantly associated (FDR  $\leq$  0.05) with TC. The red dot indicates ABO gene. B. Schematic diagram

displays the relationships among the level of TC, the risk of COVID-19 infection and different ABO

blood group. Black lines represent the associations identified in previous studies and red line means the

causal effect identified in our study.

Table 1 Summary of the MR estimates for dyslipidemia, TC, TG, LDL-c and HDL-c to the susceptibility and severity of COVID-19<sup>1</sup>

Lipid	IVW method		Weighted median method		Weighted mode-based method		MR-Egger method		FDR
	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p	
COVID-19									
Dyslipidemia	1.27(1.08, 1.49)	0.003	1.26 (1.01, 1.56)	0.040	1.22(0.93, 1.61)	0.170	1.53(1.12, 2.10)	0.020	0.013
Total Cholesterol	1.14 (1.04, 1.25)	0.005	1.23 (1.06, 1.43)	0.005	1.14 (0.99, 1.32)	0.070	1.15 (0.10, 1.33)	0.061	0.013
Triglycerides	1.18 (0.98, 1.25)	0.102	1.08 (0.90, 1.31)	0.392	1.15 (0.94, 1.41)	0.179	1.15 (0.94, 1.40)	0.170	0.128
LDL Cholesterol	1.09 (1.00, 1.18)	0.051	1.06 (0.94, 1.20)	0.358	1.06 (0.95, 1.17)	0.300	1.02 (0.91, 1.15)	0.697	0.085
HDL Cholesterol	1.03 (0.92, 1.15)	0.646	1.09 (0.91, 1.29)	0.359	1.19 (0.98, 1.44)	0.091	1.21 (0.99, 1.49)	0.073	0.646
Severe COVID-19									
Dyslipidemia	0.83(0.67, 1.02)	0.071	0.81(0.62, 1.07)	0.139	0.83(0.60, 1.14)	0.267	0.69(0.44, 1.06)	0.112	0.132
Total Cholesterol	0.95 (0.85, 1.06)	0.366	0.98 (0.81, 1.19)	0.857	1.02 (0.84, 1.24)	0.856	1.00 (0.84, 1.20)	0.993	0.366
Triglycerides	1.13 (0.99, 1.30)	0.079	1.10 (0.91, 1.33)	0.344	1.07 (0.91, 1.27)	0.420	0.99 (0.80, 1.24)	0.956	0.132
LDL Cholesterol	0.90 (0.81, 1.00)	0.049	0.95 (0.81, 1.12)	0.551	0.94 (0.81, 1.09)	0.408	0.92 (0.80, 1.07)	0.269	0.132
HDL Cholesterol	0.92 (0.81, 1.04)	0.185	0.88 (0.72, 1.08)	0.211	0.90 (0.72, 1.13)	0.361	0.89 (0.71, 1.12)	0.334	0.231

<sup>&</sup>lt;sup>1</sup> Results described MR estimates derived from the main inverse-variance weighted, MR-Egger, weighted median and weighted mode-based methods for dyslipidemia, HDL-c, LDL-c, TC and TG to the susceptibility of COVID-19 (COVID-19) and the severity of COVID-19 (Severe COVID-19). FDR refers to the *p-value* from IVW method. Values of FDR < 0.05 are marked in italic bold. *p, p-value*; CI, confidence interval.

Table 2 Summary of the observational studies for TC level in different ABO blood group<sup>1</sup>

Subjects	Cohort	Sample size	ABO blood groups	Mean level of total cholesterol	p-value	Description
Healthy blood donors	Italian	7,723	A vs. O	$183.95 \pm 0.65 \text{ vs.}$ $181.31 \pm 0.64 \text{ (mg/dL)}$	1.00 × 10 <sup>-3</sup>	The values of TC and LDL-C are significantly higher in subjects with blood group A compared with those with O blood type <sup>24</sup> .
CAD patients	Chinese	6,476	Non-O vs. O	$4.93 \pm 0.02$ vs. $4.78 \pm 0.03$ (mmol/L)	$3.80 \times 10^{-7}$	Subjects of non-O type had higher levels of TC, LDL-C, and NHDL-c $^{25}$ .
Adolescents	White	4,460	A <sub>1</sub> vs. O	Males: $174.20 \pm 0.90$ vs. $170.70 \pm 0.80$ (mg/dL) Females: $181.00 \pm 1.00$ vs. $176.10 \pm 0.90$ (mg/dL)	Male: $5.00 \times 10^{-3}$ Female: $3.00 \times 10^{-4}$	Blood group A with higher serum TC levels in white adolescents <sup>26</sup> .
Acute STEMI patients	European	1,835	Non-O vs. O	A:180.40 ± 34.50, B:182.10 ± 35.10, AB:180.50 ± 33.80 vs. O:175.30 ± 33.20 (mg/dL)	$2.30 \times 10^{-2}$	The prevalence of hyperlipidemia, TC, LDL, peak CKMB and no-reflow as well as hospitalization duration were higher in patients with non-O blood groups <sup>27</sup> .
FH patients	White	668	Non-O vs. O	9.48 ± 1.69 vs. 9.14 ± 1.73 (mmol/L)	$2.00 \times 10^{-2}$	Total cholesterol was significantly higher in non-O subjects compared to carriers of the O group <sup>28</sup> .
Coronary atherosclerosis patients	Chinese	371	Non-O vs. O	$5.05 \pm 0.07 \text{ vs.}$ $4.80 \pm 0.10 \text{ (mmol/L)}$	$4.10 \times 10^{-2}$	Subjects of non-O type had higher levels of TC, LDL-C and NHDL-C compared with that of O type <sup>29</sup> .

<sup>&</sup>lt;sup>1</sup> Table lists the published studies which demonstrate the TC level is different in diverse ABO blood group. STEMI, ST-elevation myocardial infarction; CAD, coronary artery disease; FH, familial hypercholesterolemia.

**Table 1** The MR analysis pipeline of the current study.






Figure 2. Causal effects of dyslipidemia and TC on COVID-19.



**Figure 3.** The relationships among the TC level, the susceptibility of COVID-19 and the different ABO blood group.



### **Supporting information**

**Figure S1**. Scatter plot and leave-one-out analysis plot for dyslipidemia and total cholesterol (COVID-19).

**Table S1**. Assessment of pleiotropy for dyslipidemia and blood lipids to COVID-19 and severe COVID-19.

**Table S2.** Summary of 243 genes significantly associated (FDR < 0.05) with total cholesterol.

**Table S3.** Summary of 89 biological processes significantly associated (FDR < 0.05) with total cholesterol.

**Table S4.** Summary of 20 pathways associated (p-value < 0.05) with total cholesterol.